Abstract

Objectives: The high-mobility group A protein 1a (HMGA1a) protein is known as a transcription factor that binds to DNA, but recent studies have shown it exerts novel functions through RNA-binding. We were prompted to decipher the mechanism of HMGA1a-induced alternative splicing of the estrogen receptor alpha (ERα) that we recently reported would alter tamoxifen sensitivity in MCF-7 TAMR1 cells.Methods: Endogenous expression of full length ERα66 and its isoform ERα46 were evaluated in MCF-7 breast cancer cells by transient expression of HMGA1a and an RNA decoy (2′-O-methylated RNA of the HMGA1a RNA-binding site) that binds to HMGA1a. RNA-binding of HMGA1a was checked by RNA-EMSA. In vitro splicing assay was performed to check the direct involvement of HMGA1a in splicing regulation. RNA-EMSA assay in the presence of purified U1 snRNP was performed with psoralen UV crosslinking to check complex formation of HMGA1a-U1 snRNP at the upstream pseudo-5′ splice site of exon 1.Results: HMGA1a induced exon skipping of a shortened exon 1 of ERα in in vitro splicing assays that was blocked by the HMGA1a RNA decoy and sequence-specific RNA-binding was confirmed by RNA-EMSA. RNA-EMSA combined with psoralen UV crosslinking showed that HMGA1a trapped purified U1 snRNP at the upstream pseudo-5′ splice site.Conclusions: Regulation of ERα alternative splicing by an HMGA1a-trapped U1 snRNP complex at the upstream 5′ splice site of exon 1 offers novel insight on 5′ splice site regulation by U1 snRNP as well as a promising target in breast cancer therapy where alternative splicing of ERα is involved.

Highlights

  • Cancer-associated alternative splicing has been extensively studied in various steps from tumor initiation to progression and metastasis (Oltean and Bates, 2014; Chen and Weiss, 2015)

  • We have recently found that high-mobility group A protein 1a (HMGA1a) is involved in alternative splicing of ERα (Ohe et al, 2018)

  • In addition to its DNA-binding properties exerted by its three AT hooks, we have shown HMGA1a protein binds to a specific RNA sequence of 5′-GC(U)GCUACAAG-3′, adjacently upstream the authentic 5′ splice site of exon 5 in the Presenilin2 (PS2) gene, interacts with U1-70K (Manabe et al, 2003), and traps U1 snRNP to this 5′ splice site to inhibit normal dissociation of U1 snRNP from the spliceosome and induces aberrant splicing of PS2 exon 5 (Ohe and Mayeda, 2010)

Read more

Summary

Introduction

Cancer-associated alternative splicing has been extensively studied in various steps from tumor initiation to progression and metastasis (Oltean and Bates, 2014; Chen and Weiss, 2015). These cancer-associated alternative splicing events are aberrantly regulated by multifunctional bona fide splicing factors [serine/arginine-rich (SR) proteins and heterogeneous nuclear ribonucleoproteins (hnRNPs)] and tissue-specific RNAbinding proteins (David and Manley, 2010) possessing oncogenic potential per se (Karni et al, 2007). Several recent reports have evoked attention on the importance of alternative splicing of the clinically important biomarkers in breast cancer (Inoue and Fry, 2015), and the deregulation and involvement of splicing factors in breast cancer-associated alternative splicing (Silipo et al, 2015). The resulting transcript, called ERα46 (Flouriot et al, 2000), is known for its function in partially inhibiting mitogenic activity of full length ERα (Penot et al, 2005)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call